Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Patience Grasshopper - We Wait for Optimally Compelling Data

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Apr 05, 2023 9:30am

131 Views

Post# 35380678

RE:RE:RE:Patience Grasshopper - We Wait for Optimally Compelling Data

Unmuted myself for one comment only. My wish was with the addition of Rigby and Parsons we would have a better strategy to create value here. Going to Cantor with apparently nothing more to say? They probably said to them wait for June results! Last day at Cantor today. Fingers crossed nothing more to do! GL

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity